Actimed Therapeutics

Actimed Therapeutics Ltd is a clinical-stage biopharmaceutical company headquartered in London, UK, focused on bringing innovation to the treatment of muscle wasting conditions, with a primary focus on cachexia. Actimed's main area of interest is cachexia, a debilitating condition associated with cancer and other severe chronic diseases, linked to significant morbidity and mortality. The lead product, S-pindolol (ACM-001.1), formerly known as MT-102, targets multiple pathways driving cachexia and has shown promising evidence in Phase II proof-of-concept clinical data in cachexia patients. The company is currently preparing for further clinical studies in cachexia associated with non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).